The aim of this prospective study was to evaluate the prognostic value of volumetric metabolic parameters assessed by during and after radiation-based therapy 18 F-FDG PET/CT in patients with stage III non-small cell lung cancer (NSCLC). We enrolled stage III NSCLC patients who had planned to receive definitive chemo-radiation or radiotherapy (RT) and underwent were enrolled initially. Five were excluded due to multiple metastases or double cancer. The remaining 25 patients had PET2 at a median of 46 Gy. Data on PET3 were available in 19 patients. During-RT ΔTLG (cut-off: 65%) was a significant prognostic factor for PFS (P = 0.02) and OS (P < 0.01). During-RT ΔMTV (cut-off: 42%) had marginal significance for PFS (P = 0.07) and was significant for OS (P = 0.02). Of the PET3 parameters, neither ΔTLG nor ΔMTV was a significant prognostic factor for PFS and OS. We conclude that ΔTLG of during-RT 18
| INTRODUCTION
Although about 30% of non-small cell lung cancer (NSCLC) patients presented with stage III disease at diagnosis, 1 the optimal treatment for these patients is still uncertain. Because outcomes vary broadly, stage III NSCLC is considered to present an incredibly heterogeneous disease. 2 Its standard treatment is chemoradiotherapy with the main purposes to control local disease and micrometastases. However, the reported local recurrence rates ranged from 15% to 40%. [3] [4] [5] [6] Radiation-dose escalation may improve local tumor control but side effects may also increase. 7, 8 In consideration of the disparate prognosis, early treatment response assessment of stage III NSCLC is particularly important to avoid side effects of futile treatments and to have the opportunity to change to other effective or aggressive therapy. 18 F-FDG PET, by providing metabolic information, has been widely applied in the management of oncological patients. In addition to visual interpretation, 18 F-FDG PET can offer quantitative assessment that is useful for predicting tumor response during treatment. 9 Several parameters derived from 18 F-FDG PET, such as the standardized uptake value (SUV), metabolic tumor volume (MTV), and total lesion glycolysis (TLG), have been used for tumor response assessment, including NSCLC. SUV is extensively used in clinical practice and its prognostic value in NSCLC patients has been shown. 10 However, total tumor metabolism may not be characterized only by mean or maximal SUV of the primary tumor. For example, one study revealed no additional prognostic information provided by primary tumor FDG uptake beyond that conferred by tumor size and stage. 11 On the other hand, volumetric metabolic parameters, including MTV, and TLG, which represent the complete volumetric and metabolic burden of all the tumors may have a better predictive performance than SUV. 12, 13 A meta-analysis study has also demonstrated the prognostic value of MTV and TLG in NSCLC. All the patients were treated and regularly followed according to the institutional guidelines. A definitive course of fractionated intensity-modulated radiation therapy (IMRT) with or without chemotherapy was given. For RT planning, the 
| FDG-PET/CT imaging
Each patient had three 
| Statistical analysis
Progression-free survival (PFS) was calculated as the time between the date of treatment commencement and disease progression or death, whichever occurred first. Overall survival (OS) was defined as the time between the date treatment commencement and either death or the last follow-up. To avoid overly optimistic results by datadriven selection of optimal cutoff values, 24 we used the medians of In univariate Cox proportional hazard models, only ΔTLG on PET2 was a significant factor for PFS (P = 0.02), while ΔMTV on PET2 had marginal significance (P = 0.07) ( Table 3) . Because ΔTLG and ΔMTV are highly correlated variables (ie, TLG is the product of mean SUV and MTV), these two significant metabolic parameters on PET2 were separately analyzed with other independent variables in multivariate
analysis. Both models revealed that either ΔTLG on PET2 or ΔMTV on PET2 was a prognostic factor for PFS after controlling for sex, age, histology, treatment modality and stage of disease (HR, 0.26; P = 0.04
and HR, 0.36; P = 0.05, respectively) ( Table 3) .
To further clarity whether the survival differences of these patients stratified by ΔTLG or ΔMTV on PET2 were not attributed to the effects of their pretreatment tumor burden, we analyzed if there were differences in pre-RT TLG or MTV values stratified by ΔTLG or ΔMTV of PET2 in our patients. No significant differences in the pre-RT MTV or TLG values found in patients stratified by ΔTLG on PET2
(P = 0.41 and 0.30, respectively). There were no significant differences in the pre-RT MTV or TLG values between patients stratified by ΔMTV on PET2 (P = 0.83 and 0.96, respectively).
| DISCUSSION
In this study we explored the prognostic value of volumetric metabolic parameters determined by during and after radiation-based therapy Several studies have demonstrated that pretreatment MTV or TLG were significant prognostic factors in NSCLC because they provide 3-dimensional measurements of whole body tumor burden. 12, 13 It was necessary to clarify the survival differences of patients stratified by ΔTLG on PET2 were not biased by patient's pretreatment tumor burden, so we analyzed if there were differences in pre-RT MTV or TLG. And the results showed there were no differences in pre-treatment TLG or MTV levels between stratified groups of patients, which suggests that differences in survival were attributed A previous study showed a large intra-individual heterogeneity in the evolution of SUV of the primary lung tumor during RT and different patterns of SUV changes for metabolic responders and nonresponders. 25 To know the response during RT is consequently of F-FDG uptake after the 45-Gy dose level in a patient with disease progression, so the during-RT 18 F-FDG PET was recommended to be acquired at the 50-Gy dose level or 2 weeks prior to the last dose fraction. 33 Another study with the aim of determining an optimal time window for during-RT 
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